Compare IART & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | CRVS |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1996 | 2016 |
| Metric | IART | CRVS |
|---|---|---|
| Price | $16.79 | $14.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $14.33 | ★ $30.17 |
| AVG Volume (30 Days) | 541.4K | ★ 705.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $5.64 |
| 52 Week High | $20.49 | $26.95 |
| Indicator | IART | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 46.76 |
| Support Level | $16.04 | $12.76 |
| Resistance Level | $18.78 | $16.66 |
| Average True Range (ATR) | 0.56 | 0.61 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 29.29 | 17.41 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.